Elevance Health, Inc. (ELV) Stock Analysis
Range Bound setup
Healthcare · Healthcare Plans
Sell if holding. Engine safety override at $397.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum.
Elevance Health is one of the largest U.S. health insurers with approximately 45.2 million medical members, offering commercial, Medicare and Medicaid health plans primarily under Anthem Blue Cross/Blue Shield brands across 14+ states, plus pharmacy services through CarelonRx.... Read more
Sell if holding. Engine safety override at $397.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Score 4.8/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost earnings 0.70, earnings proximity 30d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Elevance Health, Inc.
About Elevance Health, Inc.
Elevance Health served approximately 45.2 million medical members through affiliated health plans as of December 31, 2025, ranking among the largest U.S. health insurers by medical membership. Approximately 32% of total consolidated revenues came from U.S. government agencies in 2025, up from 29% in 2023. The company's Blue Cross and Blue Shield licenses span 14 states including California, Ohio, Indiana, Virginia, and New York, and in 2025 Elevance Health expanded into select service areas in Florida, Maryland, and Texas through its Simply Healthcare and Wellpoint brands.
Elevance Health earns revenue through four reportable segments: Health Benefits (risk-based and fee-based plans across commercial, Medicare, and Medicaid markets), CarelonRx (pharmacy services), Carelon Services (integrated physical, behavioral, and social care), and Corporate & Other. Commercial premiums are generally fixed for 12-month periods; Medicare Advantage revenues are based on CMS bids submitted six months before the contract year, with explicit gain and loss margin requirements. CarelonRx delegates certain core pharmacy services — including home delivery, specialty pharmacies, and claims adjudication — to CaremarkPCS Health, L.L.C. (a CVS Health Corporation subsidiary) under an agreement extending through December 31, 2027. The Medicaid business spans 24 states and Washington D.C., covering managed care for low-income populations, dual-eligible members, and specialty programs such as LTSS, CHIP, and behavioral health. Fee-based administrative services — claims processing, provider network access, and medical management — serve employer groups that self-fund benefit plans.
Show full overview
The CMS Star Rating program creates a binary revenue threshold for Elevance Health's Medicare Advantage business: plans rated at 4.0 stars or higher earn quality-based bonus payments, and plans paying minimum MLR rebates for five consecutive years face CMS contract termination. The company's 2026 Star Ratings (released October 2025, effective for 2027 bonus payments) showed approximately 59% of Medicare Advantage members enrolled in plans rated at least 4.0 stars, up from 40% under 2025 Star Ratings. Plans that lose 4.0-star status lose year-round marketing rights, which may impact membership growth depending on future CMS rating changes.
See also: Healthcare · Healthcare Plans
From Elevance Health, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-06-17Recent Developments — Elevance Health, Inc.
Latest news
- NEWS Elevance Health expects FY2026 GAAP EPS of at least $19.85 per share; Reaffirms Adj EPS of at least $26.75 per share. — benzinga Jun 10, 2026 positive
- NEWS Mizuho Maintains Outperform on Elevance Health, Raises Price Target to $465 — benzinga Jun 8, 2026 positive
- NEWS B of A Securities Maintains Buy on Elevance Health, Raises Price Target to $460 — benzinga Jun 4, 2026 positive
- NEWS Morgan Stanley Maintains Equal-Weight on Elevance Health, Raises Price Target to $404 — benzinga Jun 4, 2026 positive
- NEWS Truist Securities Maintains Buy on Elevance Health, Raises Price Target to $450 — benzinga Jun 1, 2026 positive
Generated 2026-06-17T08:36:51Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $397.80: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 54 mid-range, Bollinger mid-band. Prior stop was $374.52. Score 4.8/10, moderate confidence.
Take-profit target: $418.44 (+5.2% upside). Prior stop was $374.52. Stop-loss: $374.52.
Target reached (-5.9% upside); Quality below floor (3.8 < 4.0).
Elevance Health, Inc. trades at a P/E of 17.0 (forward 13.7). TrendMatrix value score: 6.6/10. Verdict: Sell.
29 analysts cover ELV with a consensus score of 3.8/5. Average price target: $416.
What does Elevance Health, Inc. do?Elevance Health is one of the largest U.S. health insurers with approximately 45.2 million medical members, offering...
Elevance Health is one of the largest U.S. health insurers with approximately 45.2 million medical members, offering commercial, Medicare and Medicaid health plans primarily under Anthem Blue Cross/Blue Shield brands across 14+ states, plus pharmacy services through CarelonRx. Medicaid represents 45.8% of revenue and U.S. government agencies collectively account for approximately 32% of total consolidated revenues.